VSTM news

Verastem, Inc. filed an underwriting agreement with Jefferies and Guggenheim Securities to sell 30,937,500 shares of common stock and pre-funded warrants.

Biopharma veteran Michael P. Bailey will assume the role of President and CEO on January 1, 2027, to lead the company's commercial growth and pipeline strategy.

Verastem, Inc. filed an amendment to its Note Purchase Agreement with its bondholders, the third amendment to the agreement.

Verastem Oncology exceeded expectations with $25.1M revenue and reported the first patient dosed across three registration-directed VS-7375 Phase 2 trials. The company also secured a $75M non-dilutive royalty financing, extending its cash runway into late 2027.

Verastem hosted an R&D update call discussing the KRAS G12D inhibitor VS-7375. This information is relevant for investors assessing the company's potential pipeline opportunities in the oncology space.

Verastem Oncology announced positive updated results from RAMP 205 evaluating avutometinib plus defactinib combined with standard chemotherapy in first-line metastatic pancreatic cancer, showing an 86% overall survival rate at 6 months and 52% objective response rate. The encouraging efficacy data w…